Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study

(2010) Carle Paul et al.   AMERICAN JOURNAL OF HEMATOLOGY

Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-  in a Mouse Model of Alzheimer's Disease

(2010) A. M. S. Hartz et al.   MOLECULAR PHARMACOLOGY

Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy

(2010) Elina Zotova et al.   Alzheimers Research & Therapy

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics

(2009) M. Humbert et al.   ALLERGY

Oligomers of β-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model

(2009) Renee C. Gaspar et al.   EXPERIMENTAL NEUROLOGY

Systemic inflammation and disease progression in Alzheimer disease

(2009) C. Holmes et al.   NEUROLOGY

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

(2009) Patrice Dubreuil et al.   PLoS One

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

(2009) Jacques Tebib et al.   ARTHRITIS RESEARCH & THERAPY

Brain mast cells link the immune system to anxiety-like behavior

(2008) K. M. Nautiyal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA